Aardvark Therapeutics Inc AARD

Morningstar Rating
$0.92 −0.08 (7.74%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AARD is trading at a LOCK|t@MTy? premium.
Price
$1.00
Fair Value
LOCK|Wj>C?!
Uncertainty
LOCK|lT WX^L>
1-Star Price
LOCK|xf<GD>R
5-Star Price
LOCK|&Cg#H&
Economic Moat
LOCK|hCLSw
Capital Allocation
—

News

Trading Information

Previous Close Price
$1.00
Day Range
$0.90–1.06
52-Week Range
$0.90–16.60
Bid/Ask
$0.90 / $0.93
Shares Outstanding
21.89M
Market Cap
$20.20M
Volume/Avg
241,080 / 631,006

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
28

Valuation

Metric
AARD
Price/Earnings (Normalized)
—
Price/Book Value
0.35
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
AARD
Quick Ratio
8.58
Current Ratio
9.11
Interest Coverage
—
Quick Ratio
AARD

Profitability

Metric
AARD
Return on Assets (Normalized)
−65.84%
Return on Equity (Normalized)
−72.72%
Return on Invested Capital (Normalized)
−75.90%
Return on Assets
AARD

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|wsvjRWyLOCK|^h@P$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|#%y##N?LOCK|QhW!$95B
Moderna Inc
MRNA
LOCK|T>D&?wLOCK|^rX$79B
argenx SE ADR
ARGX
LOCK|FN?st&LOCK|TN$59B
BeOne Medicines Ltd ADR
ONC
LOCK|<!M#v^@LOCK|y@$45B
Royalty Pharma PLC Class A
RPRX
LOCK|Sd<vmzkLOCK|hyQj@$30B
Incyte Corp
INCY
LOCK|$M#ZHv$LOCK|^H$23B
BioNTech SE ADR
BNTX
LOCK|Sp@ZSF%LOCK|^qj$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|wr%wmCLOCK|j?>q$19B
BridgeBio Pharma Inc
BBIO
LOCK|?%@Q%&QLOCK|!>$15B

Sponsor Center